Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangyu An

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Molecular Cancer|February 3, 2017
Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cellsParthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu, et al.
Molecular Cancer|April 19, 2025
Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cellsParthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu, et al.
Journal of Oncology|August 31, 2019
Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic CancerDongfeng Qu, Nathaniel Weygant, Jiannan Yao, et al.
International Journal of Cancer|March 27, 2018
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancerYang Ge, Nathaniel Weygant, Dongfeng Qu, et al.
Molecular and Clinical Oncology|March 21, 2014
Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patientsYi Han, Guo Li, Chongyu Su, et al.
Plos One|February 28, 2015
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cellsDongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE TrialXi Li, Li Zhang, Da Jiang, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Translational Lung Cancer Research|February 4, 2020
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancerYunpeng Yang, Bin Wu, Linian Huang, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Molecular Cancer|February 3, 2017
Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cellsParthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu, et al.
Molecular Cancer|April 19, 2025
Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cellsParthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu, et al.
Journal of Oncology|August 31, 2019
Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic CancerDongfeng Qu, Nathaniel Weygant, Jiannan Yao, et al.
International Journal of Cancer|March 27, 2018
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancerYang Ge, Nathaniel Weygant, Dongfeng Qu, et al.
Molecular and Clinical Oncology|March 21, 2014
Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patientsYi Han, Guo Li, Chongyu Su, et al.
Plos One|February 28, 2015
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cellsDongfeng Qu, Jeremy Johnson, Parthasarathy Chandrakesan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2020
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE TrialXi Li, Li Zhang, Da Jiang, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Translational Lung Cancer Research|February 4, 2020
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancerYunpeng Yang, Bin Wu, Linian Huang, et al.
Pageof 12